Overview
Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor
Status:
Terminated
Terminated
Trial end date:
2009-12-01
2009-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with resistant FSGS.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Northwell Health
Criteria
Inclusion Criteria:- Primary FSGS
- Resistance to steroids and another immunosuppressive medication
Exclusion Criteria:
- Secondary FSGS